FTH — Faeth Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1829802 ·
Last close
$27.77
Market Cap
—
52W High
$42.14
52W Low
$7.45
ADV30
404,462
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,385,000 | -16,007,000 | 189,306,000 | 26,903,000 | 16,348,000 |
| Mar 2026 | 0 | — | -170,627,000 | -170,236,000 | 205,381,000 | 152,325,000 | 342,667,000 |
| Dec 2025 | 0 | — | -4,957,000 | -4,717,000 | 22,902,000 | 8,668,000 | 4,310,000 |
| Sep 2025 | 0 | — | -4,851,000 | -4,569,000 | 27,589,000 | 10,562,000 | 4,582,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,856,000
Investing CF
$-135,678,000
Financing CF
$183,880,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
$-16,908,000
EPS Diluted TTM
$-141.82
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-469,380,000
Inventory
—
Receivables
—
ST Investments
$159,538,000
EBIT TTM
$-198,289,000
Pretax Income TTM
$-195,529,000
Interest Exp TTM
$32,000
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,288,000 | -21,085,000 | 22,902,000 | 4,310,000 | 18,592,000 | -20,453,000 |
| Dec 2024 | 0 | -31,663,000 | -30,157,000 | 45,361,000 | 6,975,000 | 38,386,000 | -24,670,000 |
| Dec 2023 | 0 | -37,064,000 | -34,101,000 | 74,374,000 | 9,479,000 | 64,895,000 | -32,023,000 |
| Dec 2022 | 0 | -50,188,000 | -48,588,000 | 118,375,000 | 14,968,000 | 103,407,000 | -39,026,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1184.78 | — |
| JNJ | JOHNSON & JOHNSON | $655.37B | $271.95 | — |
| ABBV | AbbVie Inc. | $470.55B | $266.28 | — |
| MRK | Merck & Co., Inc. | $366.84B | $148.69 | — |
| NVS | NOVARTIS AG | $279.18B | $146.88 | — |
News headlines (Yahoo Finance, 1h cache)
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
2026-09-17 20:00 · Yahoo
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
2026-09-01 16:00 · Yahoo
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-01 11:30 · Yahoo
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-28 11:30 · Yahoo
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
2026-08-14 11:30 · Yahoo
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
2026-08-07 11:30 · Yahoo
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
2026-08-04 11:30 · Yahoo
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
2026-09-08 11:30 · Yahoo
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
2026-08-24 13:55 · Yahoo
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
2026-08-17 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.